日本胃癌学会

日本臨床腫瘍学会

日本臨床薬理学会　　　

日本癌治療学会

日本癌学会

日本内科学会

日本消化器内視鏡学会

日本消化器学会

Disseminated carcinomatosis of the bone marrow from rectal cancer: A case report.

Yoshida K, Oyama T, Takahata T, Kudo S, Sato Y, Saito T, Mikami T, Itabashi C, Soma Y, Fukuda S

Clinical case reports   9 ( 3 )   1483 - 1489   2021.3

Evaluation for pharmacokinetic exposure of cytotoxic anticancer drugs in elderly patients receiving (R-)CHOP therapy.

Nakagawa J, Takahata T, Hyodo R, Chen Y, Hasui K, Sasaki K, Saito K, Ueno K, Hosoi K, Terui K, Sato A, Niioka T

Scientific reports   11 ( 1 )   785   2021.1

多発肝転移を伴う切除不能膵癌に対してFOLFIRINOX療法が著効しConversion Surgeryを施行しえた1例

赤石隆信、高畑武功他

癌と化学療法   46 ( 13 )   2551 - 2553   2019.12

A case of celiac disease with type I enteropathy-associated T-cell lymphoma in a Japanese male patient.

Hiraga H, Sakuraba H, Tanaka N, Watanabe R, Akemoto Y, Ota S, Kikuchi H, Sawaya M, Hiraga N, Chinda D, Hanabata N, Mikami T, Shimoyama T, Takahata T, Tanaka M, Fukuda S

Immunological medicine   42 ( 3 )   142 - 147   2019.9

胸水細胞診で診断しえたALK陽性未分化大細胞型リンパ腫の1例

小林弘実、小島啓子ら

青森県臨床細胞学会雑誌   36   26 - 29   2019

＜一般演題抄録＞多発肝転移を伴う切除不能膵癌に対してFOLFIRINOX療法が著効しconversion surgeryを施行し得た１例

小笠原 宏一, 石戸 圭之輔, 原 裕太郎, 赤石 隆信, 工藤 大輔, 木村 憲央, 米内山 真之介, 陳 豫, 斎藤 絢介, 高畑 武功, 佐藤 温, 袴田 健一

弘前医学   70 ( 1 )   94 - 94   2019

癌化学療法施行患者における安全性評価と苦痛度評価の差異に関する患者因子の検討

田中康平、佐藤温、高畑武功、工藤文子、齋藤絢介、陳豫

癌と化学療法   2018.6

A case of inhibitor-positive acquired von Willebrand syndrome that developed during treatment for cancer of esophagogastric junction

NAKATA Ryoko, KUSHIBIKI Mihoko, OGASAWARA Shu, TAKAHATA Takenori, SAITO Kensuke, SATO Atsushi, SHIMA Midori, KAYABA Hiroyuki

Japanese Journal of Medical Technology   67 ( 3 )   379 - 383   2018.5

GemcitabineおよびS-1治療抵抗性膵癌に対するWeekly Paclitaxel療法の後方視的検討

高畑武功、佐藤温、陳豫、齋藤絢介

癌と化学療法   2018.5

Thymus and activation-regulated chemokine elevation and lymphocytosis in a case of diffuse large B-cell lymphoma

Satoko Minakawa et al

Journal of Cutaneous Immunology and Allergy   2018.4

Intermittent withdrawal of oxaliplatin for alleviating neurotoxicity during oxaliplatin-based chemotherapy for Japanese patients with inoperable or metastatic colorectal cancer: A phase 2 multicenter study

Shunsuke Kato et al.

Tohoku J Exp Med   2018.4

食道胃接合部癌の治療中に発症したインヒビター陽性後天性von Willebrand症候群の一例

中田良子ら

医学検査   2018.3

〈一般演題抄録〉悪性腫瘍後の二次性造血器悪性腫瘍と、造血器悪性腫瘍後の二次性固形がん発症例の検討

間山 恒, 山形 和史, 高畑 武功, 鎌田 耕輔, 陳 豫, 斎藤 絢介, 玉井 佳子, 佐藤 温, 福田 眞作, 髙見 秀樹

弘前医学   68 ( 2-4 )   190   2018

A diagnostically challenging case of tuberculosis lymphadenitis

Satoko Minakawa, Takahide Kaneko, Chihiro Hagiwara, Takenori Takahata, Daisuke Sawamura

Dermatologica Sinica   34   217 - 218   2016.4

肝転移を伴う切除不能胆管癌に対して化学療法が著効した１例

脇屋太一、豊木嘉一、石戸圭之輔、工藤大輔、木村憲央、矢越雄太、石黒敦、高畑武功、佐藤温、袴田健一

癌と化学療法   2013.12

A change in the number of CCSPpos/SPCpos cells in mouse lung during development, growth, and repair

Ruowen Sun, Qiliang Zhou, Xulu Ye, Takenori Takahata, Atsushi Ishiguro, Hiroshi Kijima, Toshihiro Nukiwa, Yasuo Saijo

Respiratory Investigation   51   229 - 240   2013.4

mDCF療法が奏効し治癒手術を施行し得た経口摂取不能胃癌の１例

石黒敦、高畑武功ら

癌と化学療法   2012.3

Methylation of the KEAP1 gene promoter region in human colorectal cancer

Naoyuki Hanada, Takenori Takahata et al

BMC Cancer   2012.3

Resveratrol selectively induces DNA damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma

Tyagi Alpna, Takenori Takahata et al

Clinical Cancer Research   2011.8

Plasmablastic lymphomaの1例

廣瀬 千穂, 石黒 敦, 高畑 武功, 伊東 重豪, 西條 康夫

内科   108 ( 1 )   152 - 155   2011.7

Sequential irinotecan hydrochloride/S-1 for S-1-resistant gastric cancer: A feasible study

Takenori Takahata et al

Oncolgy Letter   2011.6

Mesenchymal stromal cells promote tumor growth through　the enhancement of neovasculization

Kazuhiro Suzuki et al

Molecular Medicine   2011.4

A case of gastric cancer with Trousseau syndrome

Shogo Kawaguchi et al

Gan To Kagaku Ryoho   36 ( 2 )   317 - 320   2009.2

20-P2-294 ワーファリンとTS-1を含む癌化学療法の併用により相互作用が疑われた症例(がん薬物療法(その他),来るべき時代への道を拓く)

照井 一史, 小田桐 奈央, 細井 一広, 佐藤 淳也, 高畑 武功, 早狩 誠

日本医療薬学会年会講演要旨集   18 ( 0 )   331   2008.9

Influence of cancer-related gene polymorphisms on clinicopathological features in colorectal cancer

Gen Yoshiya, Takenori Takahata,et al

Journal of Gastroenterology and Hepatology   23 ( 6 )   948 - 953   2008.4

[A case of unresectable advanced gallbladder cancer treated by systemic chemotherapy combined with hepatic arterial infusion].

Ishiguro A, Munakata M, Shitara K, Suzuki K, Takahata T, Itoh J, Sakata Y, Munakata A

Gan to kagaku ryoho. Cancer & chemotherapy   34 ( 7 )   1127 - 30   2007.7

[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy].

Ishiguro A, Munakata M, Shitara K, Suzuki K, Takahata T, Itoh J, Aoki M, Sakata Y, Munakata A

Gan to kagaku ryoho. Cancer & chemotherapy   34 ( 6 )   937 - 40   2007.6

Simvastatin inactivates beta 1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells

Ikuko Takeda, Shin-ichiro Maruya, Takashi Shirasaki, Hiroki Mizukami, Takenori Takahata, Jeffrey N. Myers, Seiji Kakehata, Soroku Yagihashi, Hideichi Shinkawa

CANCER SCIENCE   98 ( 6 )   890 - 899   2007.6

Chemosensitivity determinantsof CPT-11 in hepatocellular carcinoma cell lines

Takenori Takahata, Keizou Ookawa,et al

Basic Clinlcal Pharmacology ＆Toxicology   102   39 - 407   2007.4

高濃度酸素療法が有効であった高齢者腸管嚢腫様気腫症の１例

佐々木聡,高畑武功、他

市立三沢病院医誌   15 ( 1 )   33 - 36   2007.4

Abnormality of growth hormone and insulin–like growth factor I axis in advanced cancer patients

Takenori Takahata, Masaki Munakata,

Journal of Clinical Oncolory   25 ( 18S )   721s   2007.4

早期胃癌を合併したマントル細胞リンパ腫の1例

花畑憲洋、高畑武功、他

日本消化器内視鏡学会雑誌   49 ( 7 )   1674 - 1680   2007.4

S-1単剤および肝動注化学療法が奏功している切除不能進行胆のう癌の1例

石黒敦、高畑武功、他

癌と化学療法   34 ( 7 )   1127 - 1130   2007.4

Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells

Ikuko Takeda, Shin-ichiro Maruya,Takenori Takahata,et al

Cancer Science   98 ( 6 )   890 - 899   2007.4

Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in pati ents with non-small-cell lung carcinoma

Takenori Niioka, Tsukasa Uno,Takenori Takahata,et al

Cancer Chemotherapy and Pharmacology   59 ( 5 )   575 - 580   2007.4

Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma

Takenori Niioka, Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata, Mikiko Shimizu, Kazunobu Sugawara, Tomonori Tateishi

CANCER CHEMOTHERAPY AND PHARMACOLOGY   59 ( 5 )   575 - 580   2007.4

A CASE OF MANTLE CELL LYMPHOMA WITH EARLY GASTRIC CANCER

HANABATA Norihiro, MIKAMI Tatsuya, FUKUDA Shinsaku, NISHIYA Daisuke, SASAKI Satoshi, TAKAHATA Takenori, ITOH Jugoh, SASAKI Yoshihiro, KIJIMA Hiroshi, MUNAKATA Akihiro

GASTROENTEROLOGICAL ENDOSCOPY   49 ( 7 )   1674 - 1680   2007

The influence of methylated p15INK4b and p16INK4a genes on clinicopathological features in colorectal cancer

Atsushi Ishiguro, Takenori Takahata et al

Journal of Gastroenterology and Hepatology   21 ( 8 )   1334 - 1339   2006.4

経過中にmultiple lymphomatous polyposisを大腸に認めた悪性リンパ腫の一例

吉谷元、鈴木一広、高畑武功、他

青森県立中央病院医誌   51 ( 4 )   126 - 131   2006.4

日本人高齢者におけるCYP2C19変異遺伝子頻度とオメプラゾール薬物動態を指標とした生体内CYP2C19活性の検討

石澤幸男、高畑武功、他

臨床薬理の進歩   ( 27 )   82 - 87   2006.4

Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotype

Mikiko Shimizu,Takenori Takahata et al

Journal of Chromatography B Amalyt Technol Biomed Life Science   832 ( 2 )   241 - 218   2006.4

Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.

Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T

Journal of clinical pharmacology   45 ( 6 )   690 - 4   2005.6

S-1/CDDP併用化学療法が奏功した進行低分化型胃癌の1例

佐々木聡、高畑武功,他

青森県立中央病院医誌   50 ( 4 )   137 - 141   2005.4

露出腫瘤型乳頭癌の診断にて切除後、病理学的検索にて膵頭部癌と診断された1例の考察

加藤幸三、須藤晃司、高畑武功 他

弘前市立病院医誌   14 ( 1 )   19 - 24   2005.4

合流部結石の2症例

木村由佳、須藤晃司,高畑武功 他

弘前市立病院医誌   14 ( 1 )   25 - 29   2005.4

C型慢性肝炎にみられたhypovascularな脂肪原性肝腫瘍の1例

高畑武功、須藤晃司,他

弘前市立病院医誌   14 ( 1 )   35 - 40   2005.4

The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics

Yukio Ishizawa, Norio Yasui-Furukori, Takenori Takahata et al

Clin Pharmacokinet   44 ( 11 )   1179 - 1189   2005.4

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker

Takenori Takahata et al

Drugs RD   6(6)   385 - 394   2005.4

Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and itsmetabolites in subjects with different CYP2C19 genotypes

Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata et al

Journal of Clinical Pharmacology   45   690 - 694   2005.4

Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity

Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata at al

Journal of Chromatography B   816   309 - 314   2005.4

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes

Masato Saito, Norio Yasui-Furukori, Tsukasa Uno, Takenori Takahata et al

British Journal of Clinical Pharmacology   59   302 - 309   2005.4

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes

M Saito, N Yasui-Furukori, T Uno, T Takahata, K Sugawara, A Munakata, T Tateishi

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY   59 ( 3 )   302 - 309   2005.3

The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.

Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T

Clinical pharmacokinetics   44 ( 11 )   1179 - 89   2005

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

N Yasui-Furukori, M Saito, T Uno, T Takahata, K Sugawara, T Tateishi

JOURNAL OF CLINICAL PHARMACOLOGY   44 ( 11 )   1223 - 1229   2004.11

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes

N Yasui-Furukori, K Mihara, T Takahata, A Suzuki, T Nakagami, R De Vries, T Tateishi, T Kondo, S Kaneko

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY   57 ( 5 )   569 - 575   2004.5

Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study

Yukihiro Hasegawa, Shingo Takanashi,Takenori Takahata et al

Japanese Journal of Clinical Oncology   34   647 - 653   2004.4

Phase I study of 24-hr continuous hepatic arterial infusion of irinotecan (24hr HAI CPT-11) for patients with hepatocellular carcinoma (HCC)

Koji Suto, Yuh Sakata, Takenori Takahata et al

Annals of Oncology   15   106   2004.4

Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection

Tsukasa Uno, Norio Yasui-Furukori, Takenori Takahata et al

Journal of Pharmaceutical Biomedical Analysis   35   937 - 942   2004.4

Effect of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

Norio Yasui-Furukori, Masato Saito, Takenori Takahata et al

Journal of Clinical Pharmacology   44   1223 - 1229   2004.4

Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes

Norio Yasui-Furukori, Kazuo Mihara, Takenori Takahata et al

British Journal of Clinical Pharmacology   57   569 - 575   2004.4

Fexofenadine does not affect omeprazple pharmacokinetics: both are putative P-glycoprotein substrates

Takenori Takahata et al

Basic and Clinical Pharmacology and Toxicology   94   252 - 256   2004.4

Inhibition of 3T3-L1 adipocyte differentiation by 6-ethoxyzolamide: repressed peroxysome proliferator-activated receptor gamma mRNA and enhanced CCAAT/enhancer binding protein beta mRNA levels

Takenori Takahata et al

Biochemical Pharmacology   67   1667 - 1675   2004.4

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

Yasui-Furukori N, Takahata T, Nakagami T, Yoshiya G, Inoue Y, Kaneko S, Tateishi T

British journal of clinical pharmacology   57 ( 4 )   487 - 94   2004.4

CYP2C19遺伝子型別にみたオメプラゾールの代謝に与えるフルボキサミンの影響

古郡 規雄, 高畑 武功, 中神 卓, 兼子 直, 立石 智則

臨床薬理   35 ( 1 )   223S - 223S   2004

Lansoprazoleの薬物相互作用とCYP2C19遺伝子多型の関連性の検討

齋藤 正人, 古郡 規雄, 宇野 司, 高畑 武功, 菅原 和信, 棟方 昭博, 立石 智則

臨床薬理   35 ( 1 )   222S - 222S   2004

健康成人を対照とした肝硬変患者における塩酸ランジオロール臨床薬理試験

高畑 武功, 古郡 規雄, 立石 智則, 須藤 晃司, 須藤 俊之, 棟方 昭博

臨床薬理   35 ( 1 )   191S - 191S   2004

Nucleotide changes in the translated region of SCN5A from Japanese patients with Brugada syndrome and control subjects.

Takahata T, Yasui-Furukori N, Sasaki S, Igarashi T, Okumura K, Munakata A, Tateishi T

Life sciences   72 ( 21 )   2391 - 9   2003.4

CYP2C19 mutation frequency in elderly subjects living in a sparsely populated area of Shimokita peninsula (jointly worked)

Yukio Ishizawa, Takenori Takahata et al

Hirosaki Medical Journal   55   18 - 22   2003.4

Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam

N Yasui-Furukori, T Takahata, T Kondo, K Mihara, S Kaneko, T Tateishi

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY   55 ( 4 )   382 - 388   2003.4

CYP2C19 mutation frequency in elderly subjects living in a sparsely populated area of Shimokita peninsula

Ishizawa Yukio, Takahata Takenori, Yasui-Furukori Norio, Saito Masato, Sasaki Mutsuo, Tateishi Tomonori

Hirosaki Medical Journal   55 ( 1 )   18 - 22   2003

クアゼパムの吸収過程における食事摂取時間と食事中の脂肪量の影響について

古郡 規雄, 高畑 武功, 近藤 毅, 三原 一雄, 小野 真吾, 兼子 直, 立石 智則

臨床薬理   34 ( 2 )   293S - 294S   2003

Effect of dietary fat content in meals on pharmacokinetics of quazepam.

Yasui-Furukori N, Kondo T, Takahata T, Mihara K, Ono S, Kaneko S, Tateishi T

Journal of clinical pharmacology   42 ( 12 )   1335 - 40   2002.12

Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection

N Yasui-Furukori, R Furuya, T Takahata, T Tateishi

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES   768 ( 2 )   261 - 265   2002.3

Ｃａｒｂａｍａｚｅｐｉｎｅ併用によってＮｉｌｖａｄｉｐｉｎｅの降圧効果の減弱をみた症例

古郡 規雄, 高畑 武功, 立石 智則

臨床薬理   33 ( 1 )   143S - 144S   2002

Metabolism of glucocorticoid hormone by macrophage migration inhibitory factor

M Hayakari, J Kimura, T Kumano, T Takahata, S Suzuki, K Satoh, S Tsuchida

NEW DIRECTIONS FOR CELLULAR AND ORGAN TRANSPLANTATION   1210   31 - 35   2000

Pi-class glutathione transferase expression and function in mouse neoplasia

S Tsuchida, H Nakano, K Ookawa, Kakizaki, I, Hatayama, I, T Kumano, T Takahata, J Kimura, M Hayakari, K Satoh

MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY   1172   113 - 122   1999

Identification of Glutathione S-Transferase p-1 as the Class Pi Form Dominantly Expressed in Mouse Hepatic Adenomas 共著

Ookawa K, Nakano H, Kakizaki I, Hatayama I, Kajihara-Kano H, Kimura J, Hayakari M, Takahata T, Satoh K, Tsuchida S

Jpn. Cancer Res.   89 ( 6 )   641 - 648   1998

A case of nodular transformation of the liver with idiopathic portal hypertension.

TAKAHATA Takenori, SASAKI Yoshio, HIRANO Kazuhito, ISHIGURO Yoh, TAKAHASHI Toshiyuki, SUTO Koji, SUTO Toshiyuki, MUNAKATA Akihiro, YODONO Hiraku, TANAKA Masanori, KUDO Hajime, KAGE Masayoshi

Nippon Shokakibyo Gakkai Zasshi   94 ( 9 )   615 - 621   1997

抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用を目指して- V 系統別抗がん剤の副作用　化学療法薬　微小管阻害薬　微小管重合阻害薬

高畑武功、佐藤温、齋藤絢介、山形和史

日本臨床   2015.1

抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用を目指して- V 系統別抗がん剤の副作用　化学療法薬　トポイソメラーゼ阻害薬　Ⅱ型トポイソメラーゼ阻害薬（アントラサイクリン系薬剤）

佐藤温、高畑武功、齋藤絢介

日本臨床   2015.1

ハイリスクグループ（高齢者・合併症を有する患者）に対するG-CSF使用、放射線併用時の注意点およびG-CSFの有害反応

花田直之、田中諭、高畑武功、佐藤温

癌と化学療法   2014.6

ガイドラインで推奨されている薬を使い切った患者への対応は？

佐藤温、高畑武功、花田直之、田中諭

臨床腫瘍プラクティス   9 ( 2 )   162 - 168   2013.5

副作用対策のコツとピットフォール　癌治療による下痢とその対策

田中諭, 石黒敦, 高畑武功, 佐藤温

外来癌化学療法   4 ( 1 )   38 - 40   2013.2

胃癌化学療法-レジメン選択の基本

佐藤温, 高畑武功, 石黒敦, 田中諭

別冊臨床腫瘍プラクティスⅡ　消化器がん化学療法レジメン   35 - 39   2012.9

腫瘍センター市民公開講座

2018.12

骨髄移植県民公開講座

2018.11

附属病院腫瘍センターがんフェスティバル

2018.08

未来がんプロ公開シンポジウム

2018.07

がんプロ養成プラン運営協議会・懇話会

2018.07

青森県病院薬剤師会研修会

2018.03

青森乳がん塾2018

2018.01

東北臨床腫瘍研究会セミナー

2017.12

青森県民公開講座～骨髄移植を知ろう～

2017.10

がん薬物療法認定薬剤師研修会

2017.09

附属病院腫瘍センターがんフェスティバル

2017.08

青森県民公開講座　移植をもっと知ろう

2017.07

附属病院腫瘍センター市民公開講座

2016.12

がんフェスティバル

2016.08

がんプロフェッショナル市民公開講座

2016.02

附属病院腫瘍センター市民公開講座

2015.12

ブルーリボンキャラバン　もっと知ってほしい大腸がんのことin弘前

2015.09

FMアップルウェーブりんご王国紅玉カレッジ出演

2014.06

県保健師向け講義

2012.08

弘前大学健康・医療講演会（三沢）

2008.11